InflaRx NV (FRA:IF0)
€ 1.248 -0.035 (-2.73%) Market Cap: 81.61 Mil Enterprise Value: 7.62 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

InflaRx NV PANAMO Ph3 Results Call Transcript

Mar 31, 2022 / 12:30PM GMT
Jordan Zwick
InflaRx N.V. - Chief Strategy Officer

Hello. Thank you for joining us today for our presentation on the top line results from our Phase III Panama trial of Vilobelimab in severe COVID-19 patients. A replay will also be available on our website following the live event.

Before we begin, I'd like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These beliefs are subject to certain risks and uncertainties, and our actual results may differ materially.

I encourage you to consult the risk factors discussed in our SEC filings for more details. Our agenda today will include an introduction of key messages, a review of the Vilobelimab mode of action in COVID-19, the Panama trial design and Phase II results review; and finally, the Panamo Phase III trial results. We will conclude with a live Q&A session for which I will give instructions at the end of the presentation.

Today, I will be joined by our CEO, Professor Niels Riedemann; and our Chief Clinical Development Officer, Dr. Korinna Pilz. I will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot